NOVEL APPROACAHES FOR IMPROVING PEDIATRIC BRAFV600E GLIOMA PATIENT OUTCOMES

改善儿科 BRAFV600E 胶质瘤患者预后的新方法

• 批准号: 8514312
• 负责人: Charles David James
• 金额: $ 27.15万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-05-01 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8514312
• 关键词: Address; Affect; BRAF gene; Brain Neoplasms; Child; Childhood; Childhood Brain Neoplasm; Childhood Glioma; Cognitive; Cytotoxic Chemotherapy; Development; Diagnosis; Disease; Excision; FDA approved; Failure; Glioma; Gliomagenesis; Grant; Life; Malignant Childhood Neoplasm; Malignant Neoplasms; Morbidity - disease rate; Mutation; Neurologic; Oncogenes; Operative Surgical Procedures; Outcome; Patients; Radiation; Radiation therapy; Radiosurgery; Reproduction spores; Resected; Risk; Salvage Therapy; chemotherapy; driving force; improved; inhibitor/antagonist; melanoma; mouse model; novel; small molecule; therapeutic target; tumor

instnjctions):Gliomas are aggressive brain tumors that affect children. Current treatment of high-grade glioma, most ofteninvolving surgery, radiation, and cytotoxic chemotherapy, only extend median survival of affected children to14 months, and results in significant morbidity. Low-grade glioma, that cannot be completely resected aretreated with radiation, typically after failure of chemotherapy approaches, with significant resulting neuro-cognitive and developmental risks. This project addresses a specific oncogene alteration, BRAF^^¿^occurring in as many as 14% of pediatric high-grade glioma. For certain subtypes of pediatric glioma thefrequency of BRAF''^¿¿^ is much higher (66% in pleomorphic xanthoastrocytoma). Inhibitors that specificallytarget BRAF^(R)¿¿^ have been developed and have shown remarkable efficacy against melanomas that harborthis mutation. One such inhibitor, vemurafenib, has now been FDA-approved for melanoma, and is underinvestigation for treating a number of other BRAF^(R)

Instnjctions：当前的高级神经胶质瘤，最常见的手术，即认知和发育风险。 ^发生在小儿高级神经胶质瘤中的14％。挥之不去^较高（Ploomorphic Xanthoarocytoma中的66％）。挥之不去^已经开发并针对黑色素瘤表现出了显着的作用。